|
KMID : 0371420180940010019
|
|
Annals of Surgical Treatment and Research
2018 Volume.94 No. 1 p.19 ~ p.25
|
|
|
Epigenetic inactivation of RUNX3 in colorectal cancer
|
|
Shin Eung-Jin
Kim Han-Jo
Son Myoung-Won
Ahn Tae-Sung
Lee Hyun-Yong
Lim Dae-Ro
Bae Sang-Byung
Jeon Seob
Kim Hyung-Joo
Jeong Dong-Jun
Lee Moon-Soo
Kim Dong-Sun
Noh Jeong-Se
Baek Moo-Jun
|
|
|
Abstract
|
|
|
Purpose: Emerging evidence indicates that runt-related transcription factor 3 (RUNX3) is an important tumor suppressor gene in several cancer types, including colorectal cancer (CRC). However, the clinical significance of RUNX3 inactivation in CRC remains unclear. The aim of this study was to examine the correlation between clinicopathologic factors and RUNX3 hypermethylation/expression in CRC.
Methods: Sixty-two CRC patients who were treated at the Soonchunhyang University College of Medicine were recruited in this study. The hypermethylation of CpG islands in the RUNX3 promoter and the expression of RUNX3 mRNA were identified by methylation-specific polymerase chain reaction (PCR) and reverse transcriptase-PCR, respectively. The expression of RUNX3 was determined by immunohistochemical staining.
Results: Of the 62 CRC tissue samples, 20 (32.3%) presented hypermethylated RUNX3 promoters. Aberrant RUNX3 hypermethylation was found to be associated with vascular (P = 0.006) and lymphatic (P = 0.002) invasion. Hypermethylation of RUNX3 was associated with poor survival outcomes (P = 0.038). However, expression of RUNX3 was not a prognostic factor (P = 0.363).
Conclusion: Hypermethylation of RUNX3 may be a predictor of a poor prognosis in CRC.
|
|
|
KEYWORD
|
|
|
Colorectal neoplasms, Prognosis, RUNX3 protein, Methylation, Immunohistochemistry
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
   
|